Additionally, said Katherine Kraschel, assistant professor of law and health sciences at the Northeastern University School of Law, such a decision would undercut the authority of the FDA and upend the drug-approval process in ways that could drastically slow biomedical research. “It will really just undermine the FDA’s authority, and in damaging ways,” Kraschel said.